Skip to main content
Download PDF

The proportion and phenotypic changes of CD4+CD25−Foxp3+ T cells in patients with untreated rheumatoid arthritis

BMC Immunology volume 23, Article number: 41 (2022) Cite this article

Abstract

Objective

CD4+CD25+Foxp3+ regulatory T (Treg) cell-mediated immunosuppression is an essential mechanism of rheumatoid arthritis (RA). However, little is known regarding the specific role of CD4+CD25−Foxp3+ Treg cells in RA. This study aimed to investigate the frequency of circulating CD4+CD25−Foxp3+ Treg cells and their role in RA.

Methods

Sixty-one untreated RA patients and 40 healthy controls (HCs) were enrolled in this study. The proportion of CD4+CD25−Foxp3+ T cells and CD4+CD25+Foxp3+ Tregs; the levels of CTLA4, GITR, Helios, and ICOS; and the production of IL-17A, IFN-γ, and IL-10 were assessed by flow cytometry. The correlation of CD4+CD25–Foxp3+ T cells and CD4+CD25+Foxp3+ Tregs with the clinical indicators was conducted by Spearman correlation analysis.

Results

The proportion of CD4+CD25–Foxp3+ T cells was elevated in RA and positively correlated with disease activity. CD4+CD25–Foxp3+ T cells expressed less Helios and produced more IFN-γ than conventional Tregs in RA. Additionally, the proportion of CD4+CD25–Foxp3+ T cells was positively correlated with DAS28 score, IgG titer, and anti-CCP titer.

Conclusions

These data indicate that CD4+CD25−Foxp3+ T cells in RA exhibit several different functional properties from conventional Tregs and are correlated with RA disease activity.

Highlights

  • The proportion of CD4+CD25−Foxp3+ T cells was elevated in untreated RA.

  • CD4+CD25−Foxp3+ T cells expressed decreased Helios compared with Treg cells in both RA patients and HCs.

  • CD4+CD25−Foxp3+ T cells produced increased IFN-γ compared with Tregs in RA patients.

  • Elevated CD4+CD25−Foxp3+ T cells were positively correlated with DAS28 score, anti-IgG titer and anti-CCP titer.

Peer Review reports

Introduction

Rheumatoid arthritis (RA) is considered a chronic systemic autoimmune disease with excessive activation of collagen-specific T helper cells and elevated levels of autoantibodies in the serum [1]. CD4+CD25+Foxp3+ regulatory T cells (Tregs) can suppress the activity of autoreactive T cells that have escaped from the thymus and are involved in the pathogenesis of RA. Recently, a subgroup of CD4+FoxP3+ T cells negative for CD25 has been detected in multiple immune regulatory diseases, such as systemic lupus erythematosus (SLE) [2], HIV and Mycobacterium tuberculosis infection [3], and non-Hodgkin lymphoma (NHL). Bonelli M et al. demonstrated CD4+CD25–Foxp3+ T cells and Tregs with a similar phenotype [4]. However, Yang HX et al. proved that CD4+CD25–Foxp3+ T cells had suppressive activity similar to that of effector T cells and secreted IFN-γ, IL-4, IL-2, and IL-17A, although less than that of effector T cells in SLE patients [5]. An increased proportion of CD4+CD25–Foxp3+ T cells has also been reported in RA [6]. However, the functional features and clinical significance of CD4+CD25−Foxp3+ T cells remain unclear.

Therefore, the present study investigated the functional features of CD4+CD25–Foxp3+ T cells and their correlation with clinical indicators in RA patients. PBMCs were isolated from 61 untreated RA patients and 40 HCs to evaluate the proportion of CD4+CD25−Foxp3+ T cells in RA patients. Spearman correlation analysis was conducted to investigate the correlation between CD4+CD25–Foxp3+ T cells and clinical indicators. Moreover, the expression of the Treg-associated functional molecules CTLA-4 (cytotoxic T-lymphocyte associated protein 4), GITR (glucocorticoid-induced tumor necrosis factor receptor), ICOS (inducible costimulator) and Helios and the production of cytokines (IFN-γ, IL-17A, and IL-10) were analyzed to investigate the functional features of CD4+CD25–Foxp3+ T cells.

Methods

Patients

Sixty-one untreated RA and 40 HCs of comparable sex and age were recruited between October 2017 and December 2020 at the Department of Rheumatology and Immunology, the First Affiliated Hospital of Xi'an Jiaotong University. The inclusion criteria were as follows: (1) met the American College of Rheumatology/European League Against Rheumatism 2010 diagnostic criteria [7]; (2) disease-modifying anti-rheumatic drug (DMARD)-naïve patients. DMARDs included basic commonly accepted treatments and glucocorticoids. The exclusion criteria were as follows: (1) the use of any DMARD therapy; (2) pregnancy; and (3) an acute infection or any severe infection.

The disease activity index of rheumatoid arthritis was assessed by the validity of the 28-joint disease activity score using erythrocyte sedimentation rate (DAS28-ESR). RA patients were divided into the inactive RA group (DAS28 < 2.6) and active RA group (DAS28 ≥ 2.6) according to the degree of disease activity [8]. The basic characteristics and the levels of erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), rheumatoid factors (RFs), and anti-citrullinated protein antibody (anti-CCPs) were obtained on the day of sample collection. The clinical characteristics of the RA patients and HCs are shown in Table 1. Written consent for the participation of these subjects was obtained. The study protocol was approved by the ethics committee of the First Affiliated Hospital of Xi’an Jiao Tong University (Ethics number KYLLSL-2018-207).

Table 1 Characteristics of patients with RA patients and Healthy controls (HCs)
Full size table

Flow cytometric analysis of the proportion of CD4+CD25−Foxp3+ T cells and CD4+CD25+Foxp3+ Treg cells

PBMCs were isolated from venous blood (2 ml) using Ficoll-Paque™ PREMIUM (GE Healthcare Life Sciences) density-gradient centrifugation. FITC-conjugated CD4 (BD Pharmingen™, cat: 555346), PE-conjugated CD25 (BD Pharmingen™, cat: 555432), and PerCP-CyTM-conjugated CD127 (BD Pharmingen™, cat: 560551) were used for surface staining to evaluate the proportion of CD4+CD25−Foxp3+ T cells and CD4+CD25+Foxp3+ Treg cells. The cells were then fixed and permeabilized using 1 × Foxp3 Perm buffer (BD Pharmingen™) for intracellular Alexa Fluor 647-conjugated FoxP3 staining (BD Pharmingen™, cat: 560045). The proportions of CD4+CD25−Foxp3+ T cells and CD4+CD25+Foxp3+ Treg cells were acquired on a BD FACS Canto II and analyzed using FlowJo software (version 7.6.1; Tree Star).

Phenotypic and cytokine expression analysis of Treg cells

PC5.5-conjugated CD4 (BD Pharmingen™; cat: 560650), PC7-conjugated CD25 (BD Pharmingen™; cat: 557741), PB450-conjugated ICOS (BD Pharmingen™; cat: 562901) or PB450-conjugated GITR (BD Pharmingen™; cat: 747658) were used for surface staining. Consequently, the cells were fixed and permeabilized. PE-conjugated Foxp3 (BD Pharmingen™; cat: 560650), APC-conjugated CTLA4 (BD Pharmingen™; cat: 555855) or APC-conjugated Helios (BD Pharmingen™; cat: 560046) were used for intracellular staining.

To analyze the production of cytokines, PBMCs (2 × 106 cells/ml) were incubated in RPMI 1640 culture medium containing 10% fetal bovine serum (Sigma; cat no. 030M3399) with 50 ng/ml phorbol myristate acetate (PMA) (Sigma; cat: P1585-1MG) and 1 µg/ml ionomycin (Sigma; cat no. I0634-1MG) in the presence of 0.7 µl/mL GolgiStop (BD Biosciences; cat: 554724) and 1 µl/mL Golgi Plug (BD Biosciences; cat: 555029) for 6 h according to the manufacturer’s instructions. Surface staining for CD4 and CD25 and intracellular staining for Foxp3, PB450-conjugated IL-17A (BD Pharmingen™; cat: 562933), FITC-conjugated IFN-γ (BD Pharmingen™; cat: 554700), or APC–conjugated IL-10 (BD Pharmingen™; cat: 554707) were the same as described above.

Statistical analysis

Statistical analysis was performed using SPSS Statistics 22 software and GraphPad Prism 5.0 software (GraphPad Software, San Diego, CA). The Mann–Whitney U test and the Kruskal–Wallis test were used to evaluate differences between groups. Correlations were analyzed using Spearman correlation analysis. P values less than 0.05 were considered to be significant.

Results

Elevated proportions of CD4+CD25−Foxp3+ T cells and CD4+CD25+Foxp3+ Treg cells in RA patients

The median DAS28-ESR of the untreated RA patients was 4.39 (2.83–5.58). In our group, 48 patients (78.7%) were assessed as having high disease activity, and 13 patients (21.3%) were assessed as having remission. We analyzed Foxp3 in CD4+ lymphocytes subdivided according to the intensity of CD25 expression into CD4+CD25+Foxp3+ Treg cells and CD4+CD25−Foxp3+ T cells (Fig. 1a). The proportions of CD4+CD25−Foxp3+ T cells [1.00 (0.58–1.62) % vs. 0.67 (0.55–1.07) %; P < 0.05] and CD4+CD25+Foxp3+ Treg cells [7.07 (5.92–8.18) % vs. 6.31 (5.47–7.34) %; P < 0.05] were both significantly higher in the total RA patients than in the HCs. The proportions of CD4+CD25+Foxp3+ Treg cells and CD4+CD25−Foxp3+ T cells were further investigated in active RA patients and inactive RA patients. The proportion of CD4+CD25+Foxp3+ Treg cells [7.14 (6.12–8.55) % vs. 5.89 (4.75–7.65) %; P < 0.05] and CD4+CD25−Foxp3+ T cells [1.11 (0.73–1.66) % vs. 0.54 (0.41 − 1.00) %; P < 0.01] was higher in the active RA group than in the inactive RA group, and no difference was observed between the inactive RA group and HCs (Fig. 1b, c).

Fig. 1
figure 1

Elevated proportions of CD4+CD25-Foxp3+ T cells and CD4+CD25+Foxp3+ Treg cells in RA: a representative flow cytometry plots. b The proportion of CD4+CD25−Foxp3+ T cells in the PB of HCs, total untreated RA patients, inactive RA patients, and active RA patients. c The proportion of CD4+CD25+Foxp3+ Treg cells in the PB of HCs, total untreated RA patients, inactive RA patients and active RA patients. *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001. HCs, healthy controls; RA, rheumatoid arthritis.

Full size image

Phenotypic analysis of CD4+CD25−Foxp3 + T cells and CD4+CD25+Foxp3+ Treg cells

To determine whether the phenotype of CD4+CD25−Foxp3+ T cells resembled that of CD4+CD25+Foxp3+ Treg cells or CD4+CD25+Foxp3− effector T cells, we investigated molecules associated with regulation of Treg suppressive function, including CTLA-4, GITR, Helios, and ICOS, in untreated RA patients and HCs. The proportions of distinct phenotype makers were presented in Table 2. All the data were demonstrated as median [IQR, 25th-75th percentile]. The expression of Helios [58.52 (50.70–63.42) % vs. 76.18 (72.28–80.39) %; p < 0.001] on CD4+CD25−Foxp3+ T cells was significantly lower than that on CD4+CD25+Foxp3+ Treg cells in the RA group. However, no significant differences in the expression levels of CTLA4 [36.36 (28.29–42.95) % vs. 40.40 (27.40–54.00) %; p > 0.05], GITR [51.52 (32.35–61.85) % vs. 35.92 (27.18–61.66) %; p > 0.05] or ICOS [40.74 (26.86–47.78) % vs. 44.96 (35.15–51.90) %; p > 0.05] were identified between CD4+CD25−Foxp3+ T cells and CD4+CD25+Foxp3+ Treg cells in RA patients. The expression levels of CTLA4 [36.36 (28.29–42.95) % vs. 10.61 (5.93–24.91) %; p < 0.01], Helios [58.52 (50.70–63.42) % vs. 10.18 (5.04–20.56) %; p < 0.001] and ICOS [41.44 (30.73–53.78) % vs. 26.14 (15.78–30.67) %; p < 0.01] were upregulated on CD4+CD25−Foxp3+ T cells compared with CD4+CD25+Foxp3− effector T cells. This finding indicated that CD4+CD25−Foxp3+ T cells share several properties with CD4+CD25+Foxp3+ conventional Tregs in the RA group.

Table 2 Phenotypic analysis of CD4+CD25−Foxp3 + T cells and CD4+CD25+Foxp3+ Treg cells
Full size table

In addition, the expression levels of CTLA-4 [56.69 (46.61–67.39) % vs. 70.50 (60.25–74.35) %; p < 0.05] and GITR [61.40 (56.84–70.87) % vs. 75.03 (64.58–76.91) %; p < 0.05] were significantly decreased in CD4+CD25−Foxp3+ T cells compared with CD4+CD25+Foxp3+ T cells in HCs. Moreover, the expression levels of CTLA-4 [56.69 (46.61–67.39) % vs. 3.12 (2.49–12.83) %; p < 0.001], Helios [70.18 (53.33–75.60) % vs. 31.11 (3.99–42.60) %; p < 0.01] and ICOS [44.96 (35.15–51.90) % vs. 20.00 (13.60–30.17) %; p < 0.001] were significantly higher in CD4+CD25−Foxp3+ T cells compared with CD4+CD25+Foxp3− effector T cells in HCs.

We further evaluated these molecules in the RA group compared with HCs. The expression levels of CTLA4 [36.36 (28.29–42.95) % vs. 56.69 (46.61–67.39) %; p < 0.01] and GITR [51.52 (32.35–61.85) % vs. 61.40 (56.84–70.87) %; p < 0.05] in CD4+CD25−Foxp3+ T cells were lower in RA patients than in HCs. Similarly, the expression levels of CTLA4 [40.40 (27.40–54.00) % vs. 70.50 (60.25–74.35) %; p < 0.01] and GITR [35.92 (27.18–61.66) % vs. 75.03 (64.58–76.91) %; p < 0.01] in CD4+CD25+Foxp3+ Tregs were significantly decreased in RA patients compared with HCs.

Cytokines analysis of CD4+CD25−Foxp3+ T cells and CD4+CD25+Foxp3+ Treg cells

Furthermore, the cytokine profiles of IL-10, IL-17A, and IFN-γ were determined in CD4+CD25+Foxp3+ Treg cells, CD4+CD25−Foxp3+ T cells, and CD4+CD25+Foxp3− effector T cells (Table 3). The production of IFN-γ was higher in CD4+CD25−Foxp3+ T cells than in CD4+CD25+Foxp3+ Treg cells and CD4+CD25+Foxp3− effector T cells in both the RA group [10.34 (5.96–16.54) % vs. 3.72 (2.73–5.73) % vs. 6.83 (3.44–12.66) %; p < 0.05] and HCs [9.87 (4.61–11.20) % vs. 2.96 (1.57–4.28) % vs. 3.62 (3.54–4.32) %; p < 0.05]. In the HC group, the production of IL-17A [3.20 (1.85–5.51) % vs. 14.98 (8.58–19.07) %; p < 0.05] in CD4+CD25−Foxp3+ T cells was significantly lower than that in CD4+CD25+Foxp3 effector T cells. No significant difference in the production of IL-10 in CD4+CD25−Foxp3+ T cells, CD4+CD25+Foxp3+ Treg cells or CD4+CD25+Foxp3− effector T cells was observed in either RA or HCs.

Table 3 Cytokines analysis of CD4+CD25−Foxp3+ T cells and CD4+CD25+Foxp3+ Treg cells
Full size table

We further compared the production of cytokines in CD4+CD25−Foxp3+ T cells and CD4+CD25+Foxp3+ Tregs in the RA group compared with HCs. The CD4+CD25+Foxp3+ Treg cells [6.18 (5.03–13.34) % vs. 2.62 (1.58–5.36) %; p < 0.01] and CD4+CD25−Foxp3+ T cells [6.19 (3.94–8.12) % vs. 3.20 (1.85–5.51) %; p < 0.01] produced more IL-17A in the RA group than in the HC group.

The relationship of CD4+CD25−Foxp3+ T cells and CD4+CD25+Foxp3+ Treg cells with RA clinical indicators

The relationship between CD4+CD25−Foxp3+ T cells and CD4+CD25+Foxp3+ Treg cells and RA clinical indicators was further studied in these RA patients. As shown in Fig. 2a, the proportion of CD4+CD25−Foxp3+ T cells was positively correlated with the DAS28-ESR (r = 0.368; P = 0.004), serum IgG titer (r = 0.312; P = 0.042) and anti-CCP titer (r = 0.309; P = 0.049) and negatively correlated with IgM titer (r = − 0.299; P = 0.046). The proportion of CD4+CD25+Foxp3+ Treg cells was positively correlated with DAS28-ESR (r = 0.387; P = 0.002) and anti-CCP titer (r = 0.350; P = 0.025) (Fig. 2b). Our data also show that the proportion of CD4+CD25−Foxp3+ T cells was positively correlated with the swollen joint counts (r = 0.257; P = 0.046), patient reported general health (VAS) scores (r = 0.268; P = 0.037) and DAS28-CRP (r = 0.299; P = 0.019). No correlation found between tender joint counts and CD4+CD25−Foxp3+ T cells (r = 0.215; P = 0.096).

Fig. 2
figure 2

The correlation between the proportions of CD4+CD25−Foxp3+ T cells and CD4+CD25+Foxp3+ Treg cells and clinical variables. a, b The Spearman rank test was used to analyse the correlation between the CD4+CD25−Foxp3+ T cells or CD4+CD25+Foxp3+ Treg cells and DAS28-ESR, IgG titer, IgM titer, and anti-CCP titer.

Full size image

Discussion

This study demonstrated that the proportion of CD4+CD25−Foxp3+ T cells was elevated in untreated RA. The CD4+CD25−Foxp3+ T cells expressed decreased Helios compared with Treg cells in both RA patients and HCs. CD4+CD25−Foxp3+ T cells produced higher levels of IFN-γ than Tregs in RA patients. Elevated CD4+CD25−Foxp3+ T cells were positively correlated with DAS28, anti-IgG titer, and anti-CCP titer. These results indicate that CD4+CD25−Foxp3+ T cells exhibit several different functional properties from conventional Tregs.

The elevated proportions of CD4+CD25−Foxp3+ T cells detected in our study are consistent with Banesa de Paz. et al., who reported the enrichment of CD4+CD25−Foxp3+ T cells in 147 RA patients [9]. Our study also observed elevated proportions of CD4+CD25+Foxp3+ Treg cells in untreated RA patients compared with HCs. These results were consistent with several studies described previously [10,11,12]. However, Cao D, Sempere-Ortells JM, Samson Mand Kosmaczewska A, et al. reported that the proportion of Treg cells was lower in RA patients [13, 14]. The heterogeneity of RA disease, the markers identifying Treg cells, and treatment agents could be the basis for this discrepancy. This study analyzed untreated RA patients to avoid drug interference and used CD4 + CD25high and Foxp3 expression as markers of Treg cells. Furthermore, our study indicated that the proportions of CD4+CD25+Foxp3+ Treg cells and CD4+CD25−Foxp3+ T cells were increased in patients with active RA compared with those with inactive RA. In addition, the proportions of CD4+CD25+Foxp3+ Treg cells and CD4+CD25−Foxp3+ T cells were both associated with DAS28-ESR. Therefore, we speculated that the increased proportion of CD4+CD25+Foxp3+ Treg cells and CD4+CD25−Foxp3+ T cells might be due to feedback of the hyperinflammatory state in RA.

Inhibitory-related molecules are pivotal for the maintenance of Treg cell homeostasis and suppressive function [15]. Therefore, inhibitory-related molecules (CTLA-4, GITR, ICOS, and Helios) were analyzed on CD4+CD25−Foxp3+ T cells and Treg cells. CTLA-4 is constitutively expressed on Treg cells and can inhibit the expression of the costimulatory molecules CD80 and CD86 on antigen-presenting cells to suppress the activation of effector T cells [16]. GITR participates in the intransient inhibition of Treg activity and stimulation of Treg proliferation [17]. Helios, a member of the Ikaros gene transcription factor family, is expressed in a subset of Foxp3+ Tregs, which ensures Treg cells have a suppressive and anergic phenotype in the face of intense inflammatory responses. The defective expression of Helios could lead to the conversion of Treg cells into an effector T-cell phenotype that produces proinflammatory cytokines [18]. ICOS is a member of the CD28 family of costimulatory molecules and has a key role in controlling the effector functions of Treg cells [19]. Cytokine production is another important way Tregs perform suppressive functions. Treg cells are conventionally associated with the production of classical anti-inflammatory cytokines, such as IL-10, IL-35, and TGF-β. In contrast, Treg cells can also produce effector cytokines, including IFN-γ and IL-17A, under inflammatory conditions [20]. Therefore, we explored the expression of Treg-associated molecules (CTLA-4, GITR, ICOS and Helios) and the cytokine (IFN-γ, IL-17A, and IL-10) synthesis capacity in CD4+CD25–Foxp3+ T cells to investigate the functional features of CD4+CD25–Foxp3+ T cells. Our results showed that CD4+CD25−Foxp3+ T cells expressed less Helios and more IFN-γ than CD4+CD25+Foxp3+ Treg cells in RA patients. However, the expression of CTLA4, GITR, and ICOS and the production of IL-17A and IL-10 by CD4+CD25−Foxp3+ T cells were similar to those by CD4+CD25+Foxp3+ Treg cells in RA patients. These findings may indicate that CD4+CD25−Foxp3+ T cells have certain characteristics of Treg cells in RA patients. In addition, our results showed that the expression levels of CTLA4, Helios, and ICOS on CD4+CD25−Foxp3+ T cells were higher than those on CD4+CD25+Foxp3−effector T cells. These results raise the possibility that CD4+CD25−Foxp3+ T cells in RA may serve as intermediates between Treg cells and effector T cells, which combine their features. Previous studies in SLE have reached different conclusions. One study suggested that CD4+CD25−Foxp3+ T cells may have lower inhibitory function than Treg cells [21]. Another study suggested that, unlike Treg cells, CD4+CD25−Foxp3+ T cells also synthesize IFN-γ, IL-4, IL-2, and IL-17, although less than effector T cells [5]. Thus, we suggest that CD4+CD25−Foxp3+ T cells have both suppressive and proinflammatory functions in RA patients, which are between those of Treg cells and effector T cells. We also found that the proportion of CD4+CD25+Foxp3+ Treg cells from RA patients was significantly increased compared with that from HCs. However, the expression levels of CTLA-4 and GITR were both significantly decreased, and the synthesis of IL-17 was increased. Collectively, these data indicate that Tregs display a distinct phenotype, whereas the suppressive capacity of Treg cells in the PB of RA patients was defective. Treg cells may exhibit some proinflammatory features in RA.

Treg cells can suppress B-cell responses and B-cell-mediated antibody production [22]. Treg cell depletion can reduce plasma cell (PC) populations during systemic infection, and CTLA-4 deletion in Treg cells results in elevated PCs [23]. Our data showed that the proportion of CD4+CD25−Foxp3+ T cells was positively correlated with IgG titer and anti-CCP titer and negatively correlated with IgM titer. The proportion of CD4+CD25+Foxp3+ Treg cells was positively correlated with anti-CCP. This implied that the abnormal proportion and impaired suppressive function of CD4+CD25−Foxp3+ T cells and Treg cells in RA patients might be connected with autoantibody production.

In summary, we demonstrated an increased proportion of CD4+CD25−Foxp3+ T cells in untreated RA patients and was positively correlated with disease activity. Meanwhile, we suggest that CD4+CD25−Foxp3+ T cells in RA may serve as functional characteristic intermediates between Treg cells and effector T cells, which have both suppressive and proinflammatory features.

Availability of data and materials

The datasets supporting the conclusions of this article are included within the article.

Abbreviations

PB:

Peripheral blood

RA:

Rheumatoid arthritis

CTLA4:

Cytotoxic T-lymphocyte associated protein 4

GITR:

Glucocorticoid-induced tumor necrosis factor receptor

ICOS:

Inducible costimulatory

DAS28:

Disease Activity Score in 28 joints

DAS28-ESR:

The Disease Activity Score in 28 joints using the erythrocyte sedimentation rate

ESR:

Erythrocyte sedimentation rate

CRP:

C-reactive protein

RFs:

Rheumatoid factors

anti-CCP:

Anti-citrullinated protein antibodies

References

  1. Yap HY, Tee SZ, Wong MM, Chow SK, Peh SC, Teow SY. Pathogenic role of immune cells in rheumatoid arthritis: implications in clinical treatment and biomarker development. Cells. 2018;7(10):161.

    Article  CAS  Google Scholar 

  2. Horwitz DA. Identity of mysterious CD4(+)CD25(-)Foxp3(+) cells in systemic lupus erythematosus. Arthritis Res Ther. 2010;12(1):101.

    Article  Google Scholar 

  3. Angerami MT, Suarez GV, Vecchione MB, Laufer N, Ameri D, Ben G, Perez H, Sued O, Salomon H, Quiroga MF. Expansion of CD25-negative forkhead box P3-positive T cells during HIV and Mycobacterium tuberculosis infection. Front Immunol. 2017;8:528.

    Article  Google Scholar 

  4. Bonelli M, Savitskaya A, Steiner CW, Rath E, Smolen JS, Scheinecker C. Phenotypic and functional analysis of CD4+ CD25- Foxp3+ T cells in patients with systemic lupus erythematosus. J Immunol. 2009;182(3):1689–95.

    Article  CAS  Google Scholar 

  5. Yang HX, Zhang W, Zhao LD, Li Y, Zhang FC, Tang FL, He W, Zhang X. Are CD4+CD25-Foxp3+ cells in untreated new-onset lupus patients regulatory T cells? Arthritis Res Ther. 2009;11(5):R153.

    Article  Google Scholar 

  6. de Paz B, Prado C, Alperi-Lopez M, Ballina-Garcia FJ, Rodriguez-Carrio J, Lopez P, Suarez A. Effects of glucocorticoid treatment on CD25(-)FOXP3(+) population and cytokine-producing cells in rheumatoid arthritis. Rheumatology (Oxford). 2012;51(7):1198–207.

    Article  Google Scholar 

  7. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3rd, Birnbaum NS, Burmester GR, Bykerk VP, Cohen MD, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010;62(9):2569–81.

    Article  Google Scholar 

  8. Nishimoto N, Takagi N. Assessment of the validity of the 28-joint disease activity score using erythrocyte sedimentation rate (DAS28-ESR) as a disease activity index of rheumatoid arthritis in the efficacy evaluation of 24-week treatment with tocilizumab: subanalysis of the SATORI study. Mod Rheumatol. 2010;20(6):539–47.

    Article  Google Scholar 

  9. de Paz B, Prado C, Alperi-Lopez M, Ballina-Garcia FJ, Rodriguez-Carrio J, Lopez P, Suarez A. Effects of glucocorticoid treatment on CD25(-)FOXP3(+) population and cytokine-producing cells in rheumatoid arthritis. Rheumatology. 2012;51(7):1198–207.

    Article  Google Scholar 

  10. Han GM, O’Neil-Andersen NJ, Zurier RB, Lawrence DA. CD4+CD25high T cell numbers are enriched in the peripheral blood of patients with rheumatoid arthritis. Cell Immunol. 2008;253(1–2):92–101.

    Article  CAS  Google Scholar 

  11. Furuzawa-Carballeda J, Lima G, Jakez-Ocampo J, Llorente L. Indoleamine 2,3-dioxygenase-expressing peripheral cells in rheumatoid arthritis and systemic lupus erythematosus: a cross-sectional study. Eur J Clin Invest. 2011;41(10):1037–46.

    Article  CAS  Google Scholar 

  12. Kailashiya V, Singh U, Rana R, Singh NK, Dash D, Kailashiya J. Regulatory T cells and their association with serum markers and symptoms in systemic lupus erythematosus and rheumatoid arthritis. Immunol Invest. 2019;48(1):64–78.

    Article  CAS  Google Scholar 

  13. Cao D, van Vollenhoven R, Klareskog L, Trollmo C, Malmstrom V. CD25brightCD4+ regulatory T cells are enriched in inflamed joints of patients with chronic rheumatic disease. Arthritis Res Ther. 2004;6(4):R335-346.

    Article  CAS  Google Scholar 

  14. Jiao Z, Wang W, Jia R, Li J, You H, Chen L, Wang Y. Accumulation of FoxP3-expressing CD4+CD25+ T cells with distinct chemokine receptors in synovial fluid of patients with active rheumatoid arthritis. Scand J Rheumatol. 2007;36(6):428–33.

    Article  CAS  Google Scholar 

  15. Shevyrev D, Tereshchenko V. Treg heterogeneity, function, and homeostasis. Front Immunol. 2019;10:3100.

    Article  CAS  Google Scholar 

  16. Wing K, Onishi Y, Prieto-Martin P, Yamaguchi T, Miyara M, Fehervari Z, Nomura T, Sakaguchi S. CTLA-4 control over Foxp3(+) regulatory T cell function. Science. 2008;322(5899):271–5.

    Article  CAS  Google Scholar 

  17. Nocentini G, Ronchetti S, Cuzzocrea S, Riccardi C. GITR/GITRL: More than an effector T cell co-stimulatory system. Eur J Immunol. 2007;37(5):1165–9.

    Article  CAS  Google Scholar 

  18. Nakagawa H, Sido JM, Reyes EE, Kiers V, Cantor H, Kim HJ. Instability of Helios-deficient Tregs is associated with conversion to a T-effector phenotype and enhanced antitumor immunity. Proc Natl Acad Sci USA. 2016;113(22):6248–53.

    Article  CAS  Google Scholar 

  19. Simpson TR, Quezada SA, Allison JP. Regulation of CD4 T cell activation and effector function by inducible costimulator (ICOS). Curr Opin Immunol. 2010;22(3):326–32.

    Article  CAS  Google Scholar 

  20. Pandiyan P, Zhu JF. Origin and functions of pro-inflammatory cytokine producing Foxp3(+) regulatory T cells. Cytokine. 2015;76(1):13–24.

    Article  CAS  Google Scholar 

  21. Tang Y, Peng LP, Qin GX, Sun JT, Xu LJ, Jiang YF. CD4(+)CD25(-)Foxp3(+) T cells play a role in tuberculous hydrothorax rather than malignant hydrothorax. J Transl Med. 2015;13:268.

    Article  Google Scholar 

  22. Lim HW, Hillsamer P, Banham HH, Kim CH. Cutting edge: Direct suppression of B cells by CD4(+)CD25(+) regulatory T cells. J Immunol. 2005;175(7):4180–3.

    Article  CAS  Google Scholar 

  23. Zaretsky AG, Konradt C, Depis F, Wing JB, Goenka R, Atria DG, Silver JS, Cho S, Wolf AI, Quinn WJ, et al. T regulatory cells support plasma cell populations in the bone marrow. Cell Rep. 2017;18(8):1906–16.

    Article  Google Scholar 

Download references

Acknowledgements

The authors thank RA patients and HCs for their participation in this study. The authors acknowledge Professor Baojun Zhang from the School of Basic Medical Sciences, Xi’an Jiaotong University Health Science Center and Shufang Wu from the Research Center for Translational Medicine, the First Affiliated Hospital of Xi'an Jiaotong University for support with flow cytometry.

Funding

This study was supported by the Natural Science Basis Research Plan in Shaanxi Province of China (Program No. 2022JQ-958) and the institutional foundation of the First Affiliated Hospital of Xi'an Jiaotong University (2015YK10, 2018 MS-16).

Author information

Authors and Affiliations

  1. Department of Rheumatology and Immunology, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, 710061, Shaanxi, China

    Bomiao Ju, Li Zhu, Jing Wang, Jian Zheng, Zhiming Hao, Jing Luo, Jing Zhang, Nan Hu, Qi An, Xiuyuan Feng & Lan He

  2. Department of Human Anatomy and Histology and Embryology, School of Basic Medical Sciences, Xi’an Jiaotong University Health Science Center, Xi’an, 710061, Shaanxi, China

    Yongwei Huo

Authors
  1. Bomiao Ju
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Li Zhu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jing Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jian Zheng
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Zhiming Hao
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Jing Luo
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Jing Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Nan Hu
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Qi An
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Xiuyuan Feng
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Yongwei Huo
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Lan He
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

LH and JW are responsible for the study conception and design. BJ, LZ, JZ, and QA were responsible for the acquisition of data. BJ, JZ, JL, XF, YH and NH performed the data analysis and interpretation. BJ, LH, and JW contributed to writing the manuscript. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Lan He.

Ethics declarations

Ethics approval and consent to participate

The study protocol was approved by the ethics committee of the First Affiliated Hospital of Xi’an Jiao Tong University (Ethics number KYLLSL-2018-207). The research was performed according to the ethical standards of the First Affiliated Hospital of Xi’an Jiao Tong University. Written informed consent was received from all participants.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ju, B., Zhu, L., Wang, J. et al. The proportion and phenotypic changes of CD4+CD25−Foxp3+ T cells in patients with untreated rheumatoid arthritis. BMC Immunol 23, 41 (2022). https://doi.org/10.1186/s12865-022-00517-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s12865-022-00517-0

Keywords

BMC Immunology

ISSN: 1471-2172

Contact us